TL;DR
Lilly's selective amylin agonist. 20% weight loss in Phase 2. No GLP-1 receptor in sight.
What is it? Lilly's once-weekly selective amylin receptor agonist (LY3841136). An amylin analog acylated with a C20 fatty diacid. Engineered for AMY1R with 12× selectivity over the calcitonin receptor.
What does it do? Activates amylin receptors in the area postrema, hypothalamus, and nucleus tractus solitarius. Cuts caloric intake, slows gastric emptying, and suppresses postprandial glucagon. Doesn't touch GLP-1, so it layers cleanly on incretin therapy.
Does the evidence hold up? Phase 1 MAD (NCT05295940) cut weight up to 11% at 12 weeks. Phase 2 (Billings, Lancet 2025, NCT06230523) showed 20% weight loss at 9 mg vs 0.4% placebo in 263 adults. Phase 3 enrollment began end of 2025.
Who uses it? Nobody outside clinical trials. Not yet in gray-market distribution.
Bottom line? The amylin answer to the GLP-1 race. If Phase 3 holds, a non-incretin lane opens.
What It Is
Eloralintide (development code LY3841136) is an investigational once-weekly subcutaneous amylin receptor agonist being developed by Eli Lilly and Company for chronic weight management. Chemically, it is a synthetic analog of human amylin — the 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to nutrient intake — conjugated to a C20 fatty diacid that binds reversibly to serum albumin to extend plasma half-life. The engineering objective was a long-acting amylin analog with sufficient receptor selectivity to drive the satiety and body-weight effects of the amylin pathway while limiting the receptor cross-reactivity that contributes to gastrointestinal tolerability burden in non-selective agonists (notably cagrilintide).
Endogenous amylin, together with insulin, regulates postprandial glucose via three established mechanisms: slowing gastric emptying, suppressing postprandial glucagon secretion, and promoting satiety through central receptors in the area postrema and hypothalamus. Native amylin has a plasma half-life of approximately 10 minutes, making it impractical as a therapeutic. Pramlintide (Symlin®), the first amylin analog in clinical use, addressed the aggregation problem of native amylin but retained the short half-life and requires 3× daily injection at mealtime. Cagrilintide (Novo Nordisk) extended amylin therapy to once-weekly dosing using a C20 fatty diacid conjugation strategy similar to eloralintide's, and is currently paired with semaglutide as CagriSema in Phase 3 trials. Eloralintide is Lilly's answer to Novo's CagriSema — a long-acting amylin analog intended to be paired with tirzepatide in the most important head-to-head combination in the 2026 obesity pipeline.
The key differentiator Lilly emphasizes is receptor selectivity. Amylin acts at a family of related receptors formed by the calcitonin receptor (CTR) complexed with receptor activity-modifying proteins (RAMPs): AMY1R (CTR + RAMP1), AMY2R (CTR + RAMP2), and AMY3R (CTR + RAMP3), plus CTR alone. Different amylin analogs engage these receptors with different selectivity profiles, and the weight-loss and GI-tolerability effects are thought to be differentially distributed across AMY1R vs CTR / AMY3R engagement. Eloralintide was engineered to activate AMY1R approximately 12-times more potently than CTR, with reduced AMY3R activity (Briere et al., ScienceDirect 2025). This selectivity is Lilly's central commercial thesis: strong efficacy through AMY1R-mediated satiety with reduced nausea and fatigue through avoidance of broader CTR/AMY3R activation.
As of April 2026, eloralintide has completed Phase 1 and Phase 2 monotherapy trials in obesity, has additional Phase 2 programs testing combination with tirzepatide in T2D-plus-obesity populations (NCT06603571) and in monotherapy in obesity without diabetes (NCT06297616, NCT06916091), and began Phase 3 enrollment at the end of 2025 per Lilly's November 2025 Phase 2 topline announcement. It is not available outside clinical trials and is not present in the research-peptide gray market.
Mechanism of Action
Eloralintide's mechanism follows the amylin-pathway template but is distinguished by its engineered receptor-selectivity profile and pharmacokinetic properties.
- Selective AMY1R activation — Eloralintide activates the human amylin 1 receptor (AMY1R, formed by the calcitonin receptor complexed with RAMP1) approximately 12-times more potently than the human calcitonin receptor, with reduced AMY3R activity. This selectivity profile differs from cagrilintide (more broadly active at the calcitonin and amylin receptors) and is Lilly's stated engineering rationale for the observed improved GI tolerability.
- Central satiety signaling — AMY1R activation in the area postrema and nucleus tractus solitarius transmits satiety signals via brainstem-to-hypothalamic circuitry to the arcuate and paraventricular nuclei. The net effect is reduced caloric intake and smaller meal sizes — the dominant mechanism underlying weight loss in the class. Preclinical conditioned-taste-avoidance data in rats show eloralintide produces significantly less taste avoidance than cagrilintide (Briere et al., 2025), consistent with a cleaner satiety signal.
- Delayed gastric emptying — Like other amylin agonists, eloralintide slows gastric motility, flattening postprandial glucose excursions and prolonging fullness. This is both an efficacy contributor and the principal mechanism behind the nausea that some patients experience, particularly on dose escalation.
- Glucagon suppression — Amylin agonism suppresses inappropriate postprandial glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output. Relevant primarily when used in T2D patients.
- C20 fatty diacid acylation for albumin binding — Eloralintide is conjugated to a C20 fatty diacid that binds reversibly to serum albumin. This binding provides a depot effect, extends plasma half-life to support once-weekly dosing, and reduces renal clearance. The same pharmacokinetic strategy underlies semaglutide, tirzepatide, and cagrilintide.
- Mechanistic complementarity with GLP-1 agonists — Amylin and GLP-1 signal through distinct receptor systems with partially overlapping but independent satiety pathways. The rationale for eloralintide + tirzepatide combination: additive satiety signaling through non-competing receptors, potentially producing larger and more durable weight loss than either agent alone, and with the possibility of lower doses of each — reducing class-specific adverse effects.
- What it does not do — Does not activate the GLP-1 receptor, does not activate the GIP receptor, does not act on the melanocortin system. It is a single-axis amylin agonist.
- Receptor biology caveats — The AMY1R selectivity hypothesis is Lilly's framing. Whether the clean tolerability signal in Phase 2 will prove durable in Phase 3 and reflect true AMY1R-specific pharmacology or a combination of dose selection and trial-population characteristics remains to be tested at scale.
What the Research Shows
Eloralintide's evidence base as of April 2026 spans preclinical characterization, Phase 1 proof-of-concept, and a pivotal 48-week Phase 2 published in The Lancet in late 2025.
- Preclinical — discovery through clinical proof of concept (Briere et al., Mol Metab 2025) — Full translational characterization of eloralintide. In vitro: AMY1R selectivity ~12× over CTR. In rats and monkeys: favorable pharmacokinetics. In diet-induced obese rats: dose-dependent reduction of food intake and body weight, primarily through fat mass loss. Conditioned-taste-avoidance comparison: significantly less taste avoidance than cagrilintide at matched weight-loss doses (supporting the improved GI tolerability hypothesis).
- Phase 1 single-ascending dose (NCT05295940 Part A) — Evaluated doses of 0.04 to 12 mg in healthy participants. Safety and pharmacokinetic proof of concept. Plasma exposure dose-proportional at PK-relevant ranges.
- Phase 1 multiple-ascending dose (Knudsen et al., Phase 1 proof of concept report; PMID 41559929 area) — 100 participants over 12 weeks, five multiple-ascending dose cohorts. Once-weekly dosing produced up to approximately 11% bodyweight reduction after 12 weeks. Most common treatment-emergent adverse events were decreased appetite (19%), headache (12%), fatigue (11%), and COVID-19 (11%). Notably low GI adverse-event rate by amylin-class standards.
- Phase 2 pivotal trial (NCT06230523; Billings et al., Lancet 2025) — 48-week, multicenter, double-blind, randomized, placebo-controlled trial in 263 adults with obesity or overweight plus at least one weight-related comorbidity and without type 2 diabetes. Mean baseline characteristics: age 49.0 years, bodyweight 109.1 kg, BMI 39.1 kg/m², 78% female, 78% White. Randomization included fixed doses (1, 3, 6, 9 mg weekly) and two escalation arms (6–9 mg and 3–9 mg), plus placebo.
- Phase 2 efficacy — Mean percent change in bodyweight at 48 weeks: 1 mg −9% (95% CI −12.6 to −6.3); 3 mg −12% (−14.9 to −9.8); 6 mg −18% (−20.7 to −14.5); 9 mg −20% (−22.7 to −17.5); 6–9 mg escalation −20%; 3–9 mg escalation −16%; placebo −0.4%. Clear dose-response. The 9 mg dose's approximately 20% weight reduction at 48 weeks is competitive with tirzepatide's approximately 20% at 72 weeks (SURMOUNT-1) and exceeds semaglutide 2.4 mg's approximately 15% at 68 weeks (STEP-1).
- Phase 2 tolerability — Most common adverse events were nausea (placebo 14%; 1 mg 11%; 3 mg 13%; 6 mg 64%; 9 mg 33%; 6–9 mg 54%; 3–9 mg 25%) and fatigue (placebo 12%; 1 mg 0%; 3 mg 13%; 6 mg 29%; 9 mg 43%; 6–9 mg 46%; 3–9 mg 21%). The 6 mg arm's high nausea rate is notable; the slower 3–9 mg escalation arm showed substantially lower nausea (25%) with meaningful 16% weight loss — the titration design appears tolerability-critical and is likely the Phase 3 template.
- Combination with tirzepatide — ongoing (NCT06603571) — Phase 2 study evaluating eloralintide alone or in combination with tirzepatide in adults with obesity or overweight and T2D. Topline not yet public as of April 2026. The combination is the probable commercial vehicle for eloralintide in the obesity market if the monotherapy Phase 3 supports approval.
- Additional Phase 2 monotherapy programs (NCT06297616, NCT06916091) — Additional Phase 2 work expanding the monotherapy database ahead of Phase 3 enrollment.
- Phase 3 initiated — Lilly announced November 6, 2025 that Phase 3 enrollment in obesity monotherapy would begin by year-end 2025 based on the Phase 2 Lancet result.
Research Context — A Strong Phase 2, Not Yet a Phase 3
Eloralintide's Phase 2 weight-loss result (up to 20% at 48 weeks) is one of the most compelling amylin-class data sets published to date. The improved GI tolerability relative to cagrilintide — if it holds — is a clinically meaningful differentiation. But a single Phase 2 is not a Phase 3; enrollment size, trial duration, and broader patient population in Phase 3 can change the safety and efficacy picture. The 6 mg fixed-dose nausea rate (64%) also illustrates that eloralintide is not a nausea-free drug — titration matters. Watch for Phase 3 topline in 2027 timeframe.
Human Data
All currently published eloralintide human data comes from Lilly's clinical-trial program. There is no off-label or gray-market human experience.
- NCT05295940 — Phase 1 single- and multiple-ascending dose — Safety, PK, and weight-loss proof of concept in healthy participants and adults with obesity. Up to ~11% bodyweight reduction at 12 weeks in the MAD portion. Favorable GI tolerability relative to amylin-class expectations.
- NCT06230523 — Phase 2 monotherapy obesity (Billings et al., Lancet 2025) — 263 adults, 48 weeks, dose-response and titration-design evaluation. Pivotal efficacy and tolerability data summarized above.
- NCT06297616 — Phase 2 monotherapy extension — Additional Phase 2 data in obesity monotherapy. Specific endpoints and topline status per Lilly's pipeline reporting.
- NCT06916091 — Phase 2 monotherapy study — Additional Phase 2 program expanding the dataset.
- NCT06603571 — Phase 2 eloralintide ± tirzepatide in T2D + obesity — The combination program. Topline expected to influence Phase 3 design for both monotherapy and combination arms.
- NCT06345066, NCT06916065 — additional tirzepatide-combination programs — Extended Phase 2 evaluation of the combination in different populations.
- Phase 3 enrollment initiated end of 2025 — ClinicalTrials.gov registry expected to add Phase 3 monotherapy and combination protocols in early 2026.
- No off-trial human use — Eloralintide is not commercially available, not compounded, not sold through research-chemical channels. Any source claiming to offer "eloralintide" outside the Lilly trial network is almost certainly selling a counterfeit or mislabeled product.
Dosing from the Literature
Doses below summarize what has appeared in the Phase 1 and Phase 2 programs. No approved dose exists. Phase 3 protocols will finalize the labeled starting, titration, and maintenance doses.
| Dose / Schedule | Source | Outcome | Notes |
|---|
| 0.04–12 mg single dose | NCT05295940 Part A (Phase 1 SAD) | PK dose-proportional | Safety and PK characterization. No efficacy endpoint. |
| Multiple ascending, 12 weeks | Phase 1 MAD | Up to ~11% weight loss | Favorable GI tolerability vs class. |
| 1 mg weekly × 48 weeks | NCT06230523 | −9% weight (Lancet 2025) | Low-end dose; low nausea (11%). |
| 3 mg weekly × 48 weeks | NCT06230523 | −12% weight | Low nausea (13%). |
| 6 mg weekly × 48 weeks | NCT06230523 | −18% weight | High nausea rate (64%) with direct 6 mg start. |
| 9 mg weekly × 48 weeks | NCT06230523 | −20% weight | Highest efficacy. Nausea 33% (after gradual exposure). |
| 6→9 mg escalation | NCT06230523 | −20% weight | Matches 9 mg direct for efficacy. Nausea 54%. |
| 3→9 mg escalation | NCT06230523 | −16% weight | Best tolerability of high-dose arms. Nausea 25%, fatigue 21%. |
Dosing Disclaimer
Eloralintide is investigational. No approved dose exists. The Phase 3 labeled-dose regimen will be determined by Lilly's Phase 3 protocols and FDA labeling discussions. Current Phase 2 data strongly suggest that slower titration (3→9 mg) provides similar weight loss to direct higher-dose starts with substantially better tolerability. Anyone seeing eloralintide sold outside a registered clinical trial should assume the product is counterfeit; accept no "research chemical" source of this molecule.
Reconstitution & Storage
Trial-supplied eloralintide has been provided as a pre-formulated solution; no investigator or subject reconstitution has been described in the published literature. Commercial presentation (if approved) is likely to follow Lilly's pre-filled pen / multi-dose pen platform established for tirzepatide.
| Form (anticipated) | Concentration | Storage | Notes |
|---|
| Trial solution (SubQ) | Per trial protocol | 2–8°C refrigerated | Protocol-specific handling; not publicly published. |
| Commercial pen (anticipated) | Dose-strength-specific | 2–8°C refrigerated long-term | Projected to follow Lilly tirzepatide-pen handling. |
| Room temperature window (anticipated) | — | Limited-time (<30°C) | Consistent with Lilly's other fatty-acid-acylated peptides. |
- Subcutaneous injection — Abdomen, thigh, or upper arm. Once-weekly dosing. No IV or IM administration.
- Albumin-bound PK — The C20 fatty diacid depot binding to albumin provides the weekly dosing interval; no special handling to preserve this beyond standard cold-chain.
- Stability — Not freeze-stable; protect from freezing and from direct sunlight.
- Not reconstituted by the user — Trial and (anticipated) commercial presentations are ready-to-inject.
→ Use the Kalios Dosing Calculator for weekly SubQ scheduling
Side Effects & Risks
Important
Eloralintide is Phase 2 and not FDA-approved. Expect amylin-class GI effects. Combining it with tirzepatide is untested in humans. This is a doctor conversation.
Side effects in the Phase 2 NCT06230523 trial were dominated by amylin-class GI and metabolic effects, with the magnitude strongly influenced by dose and titration approach.
- Nausea — the dominant side effect — Rates were strongly dose- and titration-dependent in the Phase 2: 11% at 1 mg, 13% at 3 mg, 64% at direct 6 mg, 33% at 9 mg (after prior exposure), 25% at 3→9 mg escalation, and 14% in placebo. Slower titration substantially reduced nausea without sacrificing weight loss.
- Fatigue — Also dose-dependent: 0% at 1 mg, rising to 43% at 9 mg fixed. Lower in gradual escalation arms.
- Vomiting and diarrhea — Amylin-class GI profile. Generally milder than nausea. Resolves with continued dosing in most patients.
- Decreased appetite — Expected; classified as both a therapeutic effect and, occasionally, an adverse event when extreme.
- Injection site reactions — Mild, typical SubQ peptide profile.
- Hypoglycemia — Low risk as monotherapy in non-diabetics (amylin agonists do not directly cause hypoglycemia). Risk rises when combined with insulin or sulfonylureas.
- No thyroid C-cell tumor signal to date — Unlike GLP-1 agonists, amylin analogs have not surfaced the rodent thyroid C-cell signal. The FDA labeling for any future approval will depend on the full nonclinical package.
- Pancreatitis — Not flagged in the eloralintide Phase 2 topline. The amylin class does not carry the same pancreatitis signal as GLP-1 agonists, but broader post-marketing surveillance is pending.
- Gallbladder — Rapid weight loss across the obesity pharmacology class carries a modest cholelithiasis / cholecystitis signal; eloralintide should be watched for this class effect in Phase 3.
- Pregnancy and lactation — Limited data; contraindicated in trials and presumed contraindicated on approval pending pharmacovigilance.
- Drug interactions — Delayed gastric emptying may alter oral drug absorption. Specific interaction studies will accompany any NDA.
- Immunogenicity — A theoretical concern for any acylated peptide biologic. Phase 2 did not surface clinically meaningful anti-drug antibody signals per the published Lancet abstract.
- Counterfeit risk — Any source claiming to offer eloralintide outside a registered trial is selling counterfeit material. This is the single largest practical risk for anyone tempted to pursue the compound early.
Bloodwork & Monitoring
No FDA-approved monitoring framework exists yet. Likely monitoring (drawing on trial protocols and amylin-class expectations):
- Body weight and waist circumference — Primary efficacy endpoint.
- Fasting glucose and HbA1c — Metabolic status tracking, relevant for T2D-combination programs.
- Fasting insulin and C-peptide — Insulin sensitivity and beta-cell function markers.
- Lipid panel — Typical weight-loss-associated changes (reduced triglycerides, increased HDL, modest LDL shifts).
- Hepatic function (AST/ALT) — Weight loss often improves NAFLD markers; baseline prudent.
- Renal function (eGFR) — Standard.
- CBC — Standard clinical trial surveillance.
- Symptom tracking — Nausea, fatigue, appetite. Formal PRO instruments used in Phase 2 and Phase 3.
- DXA or bioimpedance (optional) — Body composition for fat-mass-specific tracking. Preclinical data suggest eloralintide-driven weight loss is primarily fat mass.
Commonly Stacked With
The most important combination partner. Phase 2 NCT06603571 is evaluating eloralintide alone or combined with tirzepatide in adults with obesity + T2D. Mechanistically complementary: tirzepatide engages GIP and GLP-1 receptors; eloralintide selectively engages AMY1R. Anticipated to produce additive or multiplicative weight loss with improved tolerability at lower doses of each. Lilly's commercial answer to Novo's CagriSema (cagrilintide + semaglutide).
Novo Nordisk's long-acting amylin analog. Same drug class, broader receptor activity (non-selective). Cagrilintide is the established amylin comparator; eloralintide's preclinical taste-avoidance and Phase 2 tolerability data position it as the selective-receptor challenger in this class.
Mechanistically similar to the CagriSema logic (GLP-1 + amylin). Not part of Lilly's declared combination program with eloralintide but biologically plausible. Lilly will commercially pursue tirzepatide-combo rather than cross-company semaglutide pairing.
GLP-1 / GIP / glucagon tri-agonist in Phase 3. The other next-generation Lilly obesity asset. Retatrutide and eloralintide may become complementary Lilly products addressing different patient segments and combination possibilities.
Standard obesity-care lifestyle interventions
Intensive behavioral therapy (dietary counseling, physical activity, behavioral modification) was the background in the eloralintide Phase 2. Drug effects are layered on top of lifestyle support, not a substitute for it.
→ Check compound compatibility in the Stack Builder
Regulatory Status
Current Status — April 2026
Eloralintide is investigational. It has no FDA, EMA, or other major-regulator approval. The compound has completed Phase 1 and the pivotal 48-week Phase 2 monotherapy obesity trial (NCT06230523; Billings et al., Lancet 2025). Lilly announced November 6, 2025 that Phase 3 enrollment in obesity monotherapy would begin by year-end 2025. Phase 2 combination work with tirzepatide (NCT06603571) is ongoing.
Eloralintide is not on the FDA Category 2 Bulk Drug Substances list and not part of HHS Secretary Robert F. Kennedy Jr.'s February 2026 reclassification announcement. As an investigational NDA-track biologic developed by Eli Lilly, it exists entirely within the conventional pharmaceutical regulatory framework.
WADA: Not specifically named on the WADA Prohibited List as of the 2026 edition. Amylin-class compounds do not fall cleanly into S-class categories; tested athletes in weight-category sports should consult their federation. This is hypothetical for eloralintide in 2026 given the lack of availability outside trials.
Cost & Access
Eloralintide is available only through Lilly-sponsored clinical trials. It is not sold as a research chemical, not available through compounding pharmacies, and not available through any international pharmacy import channel. Clinical-trial participation is the only legitimate access route — see ClinicalTrials.gov for open Phase 2/3 studies (NCT06230523 completed; active programs include NCT06297616, NCT06603571, NCT06916091, NCT06345066, NCT06916065, plus upcoming Phase 3 registrations).
Following approval (anticipated no sooner than 2027–2028 pending Phase 3 timelines), eloralintide is likely to be priced in line with the other Lilly obesity biologics and dispensed through specialty pharmacy channels on prescription. Commercial-coverage and access patterns will evolve with labeling.
Any product being marketed as "eloralintide" outside Lilly's clinical-trial network as of April 2026 is counterfeit. Accept no research-chemical or gray-market source for this molecule — both the legal and the clinical risk are unambiguous.
Estimated pricing as of April 2026. Actual costs vary by provider, location, and prescription status. Kalios does not sell compounds.
Related Compounds
People researching Eloralintide often also look at these:
Synthetic amylin analogue (Symlin). Post-prandial glucose and satiety modulator.
Fixed-dose combination of cagrilintide + semaglutide. Amylin + GLP-1 obesity protocol.
Daily GLP-1 receptor agonist (Victoza / Saxenda). First-generation GLP-1 with shorter half-life.
Key References
- Billings LK, Hansen HH, Dam-Larsen S, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025. PMID: 41207310. (NCT06230523 — pivotal Phase 2; up to 20% weight loss at 9 mg over 48 weeks.)
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. 2025. PMID: 41559929. (Phase 1 multiple-ascending-dose results; 100 participants, up to ~11% weight loss at 12 weeks.)
- Briere DA, Bueno AB, Gimeno RE, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025. PMID: 41109426. (Full translational characterization; AMY1R selectivity, preclinical weight loss, conditioned-taste-avoidance comparison vs cagrilintide.)
- Briere DA, Long A, Bullock DM, et al. 849-P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide. Diabetes 2025;74(Suppl 1):849-P. (ADA 2025 scientific sessions preclinical comparison.)
- Eli Lilly and Company. Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight. Press release, November 6, 2025. (Phase 2 topline announcement; Phase 3 enrollment initiation.)
- ClinicalTrials.gov NCT05295940 — A Study of LY3841136 in Healthy Participants. (Phase 1 SAD/MAD.)
- ClinicalTrials.gov NCT06230523 — A Study of LY3841136 in Adult Participants With Obesity or Overweight. (Pivotal Phase 2.)
- ClinicalTrials.gov NCT06603571 — A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes. (Combination Phase 2.)
- ClinicalTrials.gov NCT06297616, NCT06916091 — Additional Phase 2 eloralintide monotherapy programs.
- Lutz TA. The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integr Comp Physiol. 2010;298(6):R1475-R1484. PMID: 20357017.
- Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev. 2015;67(3):564-600. PMID: 26071591.
- Boyle CN, Lutz TA, Le Foll C. Amylin — Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. Mol Metab. 2018;8:203-210. PMID: 29203236.
- Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus. Nat Rev Endocrinol. 2025;21:482-494. (Modern review of the amylin drug class including eloralintide context.)
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. PMID: 34798049. (Cagrilintide Phase 2 — the class comparator.)
- Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730. PMID: 37515693. (CagriSema Phase 2 — the combination benchmark.)
Last updated: April 2026 | Profile authored by Kalios Peptides research team